Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma.

Duits LC, Lao-Sirieix P, Wolf WA, O'Donovan M, Galeano-Dalmau N, Meijer SL, Offerhaus GJA, Redman J, Crawte J, Zeki S, Pouw RE, Chak A, Shaheen NJ, Bergman JJGHM, Fitzgerald RC.

Dis Esophagus. 2019 Jan 1;32(1). doi: 10.1093/dote/doy102.

PMID:
30496496
2.

Optimal Histologic Cutpoints for Treatment Response in Patients With Eosinophilic Esophagitis: Analysis of Data From a Prospective Cohort Study.

Reed CC, Wolf WA, Cotton CC, Rusin S, Perjar I, Hollyfield J, Woosley JT, Shaheen NJ, Dellon ES.

Clin Gastroenterol Hepatol. 2018 Feb;16(2):226-233.e2. doi: 10.1016/j.cgh.2017.09.046. Epub 2017 Oct 4.

3.

Healthcare provider education to support integration of pharmacogenomics in practice: the eMERGE Network experience.

Rohrer Vitek CR, Abul-Husn NS, Connolly JJ, Hartzler AL, Kitchner T, Peterson JF, Rasmussen LV, Smith ME, Stallings S, Williams MS, Wolf WA, Prows CA.

Pharmacogenomics. 2017 Jul;18(10):1013-1025. doi: 10.2217/pgs-2017-0038. Epub 2017 Jun 22.

4.

Six-Food Elimination Diet and Topical Steroids are Effective for Eosinophilic Esophagitis: A Meta-Regression.

Cotton CC, Eluri S, Wolf WA, Dellon ES.

Dig Dis Sci. 2017 Sep;62(9):2408-2420. doi: 10.1007/s10620-017-4642-7. Epub 2017 Jun 12. Review.

5.

Late Recurrence of Barrett's Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial.

Cotton CC, Wolf WA, Overholt BF, Li N, Lightdale CJ, Wolfsen HC, Pasricha S, Wang KK, Shaheen NJ; AIM Dysplasia Trial Group.

Gastroenterology. 2017 Sep;153(3):681-688.e2. doi: 10.1053/j.gastro.2017.05.044. Epub 2017 Jun 1.

6.

Concordance between Research Sequencing and Clinical Pharmacogenetic Genotyping in the eMERGE-PGx Study.

Rasmussen-Torvik LJ, Almoguera B, Doheny KF, Freimuth RR, Gordon AS, Hakonarson H, Hawkins JB, Husami A, Ivacic LC, Kullo IJ, Linderman MD, Manolio TA, Obeng AO, Pellegrino R, Prows CA, Ritchie MD, Smith ME, Stallings SC, Wolf WA, Zhang K, Scott SA.

J Mol Diagn. 2017 Jul;19(4):561-566. doi: 10.1016/j.jmoldx.2017.04.002. Epub 2017 May 11.

7.

A visual analogue scale and a Likert scale are simple and responsive tools for assessing dysphagia in eosinophilic oesophagitis.

Reed CC, Wolf WA, Cotton CC, Dellon ES.

Aliment Pharmacol Ther. 2017 Jun;45(11):1443-1448. doi: 10.1111/apt.14061. Epub 2017 Mar 31.

8.

Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis.

Kroep S, Heberle CR, Curtius K, Kong CY, Lansdorp-Vogelaar I, Ali A, Wolf WA, Shaheen NJ, Spechler SJ, Rubenstein JH, Nishioka NS, Meltzer SJ, Hazelton WD, van Ballegooijen M, Tramontano AC, Gazelle GS, Luebeck EG, Inadomi JM, Hur C.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1471-1474. doi: 10.1016/j.cgh.2016.12.034. Epub 2017 Jan 12. No abstract available.

9.

Cost Utility Analysis of Topical Steroids Compared With Dietary Elimination for Treatment of Eosinophilic Esophagitis.

Cotton CC, Erim D, Eluri S, Palmer SH, Green DJ, Wolf WA, Runge TM, Wheeler S, Shaheen NJ, Dellon ES.

Clin Gastroenterol Hepatol. 2017 Jun;15(6):841-849.e1. doi: 10.1016/j.cgh.2016.11.032. Epub 2016 Dec 7.

10.

Association Between Body Mass Index and Clinical and Endoscopic Features of Eosinophilic Esophagitis.

Wolf WA, Piazza NA, Gebhart JH, Rusin S, Covey S, Higgins LL, Beitia R, Speck O, Woodward K, Cotton CC, Runge TM, Eluri S, Woosley JT, Shaheen NJ, Dellon ES.

Dig Dis Sci. 2017 Jan;62(1):143-149. doi: 10.1007/s10620-016-4357-1. Epub 2016 Oct 24.

11.

Practical considerations for implementing genomic information resources. Experiences from eMERGE and CSER.

Rasmussen LV, Overby CL, Connolly J, Chute CG, Denny JC, Freimuth R, Hartzler AL, Holm IA, Manzi S, Pathak J, Peissig PL, Smith M, Williams MS, Shirts BH, Stoffel EM, Tarczy-Hornoch P, Rohrer Vitek CR, Wolf WA, Starren J.

Appl Clin Inform. 2016 Sep 21;7(3):870-82. doi: 10.4338/ACI-2016-04-RA-0060.

12.

Creating a scalable clinical pharmacogenomics service with automated interpretation and medical record result integration - experience from a pediatric tertiary care facility.

Manzi SF, Fusaro VA, Chadwick L, Brownstein C, Clinton C, Mandl KD, Wolf WA, Hawkins JB.

J Am Med Inform Assoc. 2017 Jan;24(1):74-80. doi: 10.1093/jamia/ocw052. Epub 2016 Jun 14.

PMID:
27301749
13.

Food-specific IgG4 is associated with eosinophilic esophagitis.

Wright BL, Kulis M, Guo R, Orgel KA, Wolf WA, Burks AW, Vickery BP, Dellon ES.

J Allergy Clin Immunol. 2016 Oct;138(4):1190-1192.e3. doi: 10.1016/j.jaci.2016.02.024. Epub 2016 Apr 6. No abstract available.

14.

Evaluation of Histologic Cutpoints for Treatment Response in Eosinophilic Esophagitis.

Wolf WA, Cotton CC, Green DJ, Hughes JT, Woosley JT, Shaheen NJ, Dellon ES.

J Gastroenterol Hepatol Res. 2015 Oct 1;4(10):1780-1787. Epub 2015 Oct 21.

15.

Racial differences in dietary changes and quality of life after a colorectal cancer diagnosis: a follow-up of the Study of Outcomes in Colorectal Cancer Survivors cohort.

Lewis CM, Wolf WA, Xun P, Sandler RS, He K.

Am J Clin Nutr. 2016 Jun;103(6):1523-30. doi: 10.3945/ajcn.115.126276. Epub 2016 Apr 20.

16.

The extremely narrow-caliber esophagus is a treatment-resistant subphenotype of eosinophilic esophagitis.

Eluri S, Runge TM, Cotton CC, Burk CM, Wolf WA, Woosley JT, Shaheen NJ, Dellon ES.

Gastrointest Endosc. 2016 Jun;83(6):1142-8. doi: 10.1016/j.gie.2015.11.019. Epub 2015 Dec 1. Erratum in: Gastrointest Endosc. 2016 Oct;84(4):755.

17.

When Participants in Genomic Research Grow Up: Contact and Consent at the Age of Majority.

Brothers KB, Holm IA, Childerhose JE, Antommaria AH, Bernhardt BA, Clayton EW, Gelb BD, Joffe S, Lynch JA, McCormick JB, McCullough LB, Parsons DW, Sundaresan AS, Wolf WA, Yu JH, Wilfond BS; Pediatrics Workgroup of the Clinical Sequencing Exploratory Research (CSER) Consortium; Pediatrics Workgroup of the Clinical Sequencing Exploratory Research CSER Consortium.

J Pediatr. 2016 Jan;168:226-31.e1. doi: 10.1016/j.jpeds.2015.09.020. Epub 2015 Oct 23. No abstract available.

18.

Spatial predisposition of dysplasia in Barrett's esophagus segments: a pooled analysis of the SURF and AIM dysplasia trials.

Cotton CC, Duits LC, Wolf WA, Peery AF, Dellon ES, Bergman JJ, Shaheen NJ.

Am J Gastroenterol. 2015 Oct;110(10):1412-9. doi: 10.1038/ajg.2015.263. Epub 2015 Sep 8.

19.

Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus.

Wolf WA, Pasricha S, Cotton C, Li N, Triadafilopoulos G, Muthusamy VR, Chmielewski GW, Corbett FS, Camara DS, Lightdale CJ, Wolfsen H, Chang KJ, Overholt BF, Pruitt RE, Ertan A, Komanduri S, Infantolino A, Rothstein RI, Shaheen NJ.

Gastroenterology. 2015 Dec;149(7):1752-1761.e1. doi: 10.1053/j.gastro.2015.08.048. Epub 2015 Aug 29.

20.

Effects of the Learning Curve on Efficacy of Radiofrequency Ablation for Barrett's Esophagus.

Pasricha S, Cotton C, Hathorn KE, Li N, Bulsiewicz WJ, Wolf WA, Muthusamy VR, Komanduri S, Wolfsen HC, Pruitt RE, Ertan A, Chmielewski GW, Shaheen NJ.

Gastroenterology. 2015 Oct;149(4):890-6.e2. doi: 10.1053/j.gastro.2015.06.012. Epub 2015 Jun 25.

21.

Reply: To PMID 25086190.

Wolf WA, Dellon ES.

Clin Gastroenterol Hepatol. 2015 Sep;13(9):1702. doi: 10.1016/j.cgh.2015.05.008. Epub 2015 May 10. No abstract available.

22.

Recurrent intestinal metaplasia after radiofrequency ablation for Barrett's esophagus: endoscopic findings and anatomic location.

Cotton CC, Wolf WA, Pasricha S, Li N, Madanick RD, Spacek MB, Ferrell K, Dellon ES, Shaheen NJ.

Gastrointest Endosc. 2015;81(6):1362-9. doi: 10.1016/j.gie.2014.12.029. Epub 2015 Mar 24.

23.

Electronic medical records and genomics (eMERGE) network exploration in cataract: several new potential susceptibility loci.

Ritchie MD, Verma SS, Hall MA, Goodloe RJ, Berg RL, Carrell DS, Carlson CS, Chen L, Crosslin DR, Denny JC, Jarvik G, Li R, Linneman JG, Pathak J, Peissig P, Rasmussen LV, Ramirez AH, Wang X, Wilke RA, Wolf WA, Torstenson ES, Turner SD, McCarty CA.

Mol Vis. 2014 Sep 19;20:1281-95. eCollection 2014.

24.

Practical guidance on informed consent for pediatric participants in a biorepository.

Brothers KB, Lynch JA, Aufox SA, Connolly JJ, Gelb BD, Holm IA, Sanderson SC, McCormick JB, Williams JL, Wolf WA, Antommaria AH, Clayton EW.

Mayo Clin Proc. 2014 Nov;89(11):1471-80. doi: 10.1016/j.mayocp.2014.07.006. Epub 2014 Sep 26. No abstract available.

25.

Evidence for fibroblast growth factor-2 as a mediator of amphetamine-enhanced motor improvement following stroke.

Wolf WA, Martin JL, Kartje GL, Farrer RG.

PLoS One. 2014 Sep 17;9(9):e108031. doi: 10.1371/journal.pone.0108031. eCollection 2014.

26.

Esophageal diseases.

Wolf WA, Dellon ES, Shaheen NJ.

Endoscopy. 2014 Sep;46(9):767-71. doi: 10.1055/s-0034-1377508. Epub 2014 Aug 18. Review. No abstract available.

27.

Esophageal diseases.

Wolf WA, Dellon ES, Shaheen NJ.

Gastrointest Endosc. 2014 Sep;80(3):374-9. doi: 10.1016/j.gie.2014.07.001. Review. No abstract available.

28.

Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients.

Wolf WA, Cotton CC, Green DJ, Hughes JT, Woosley JT, Shaheen NJ, Dellon ES.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):452-8. doi: 10.1016/j.cgh.2014.07.034. Epub 2014 Jul 30. Erratum in: Clin Gastroenterol Hepatol. 2015 May;13(5):1031. Dosage error in article text.

29.

Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems.

Rasmussen-Torvik LJ, Stallings SC, Gordon AS, Almoguera B, Basford MA, Bielinski SJ, Brautbar A, Brilliant MH, Carrell DS, Connolly JJ, Crosslin DR, Doheny KF, Gallego CJ, Gottesman O, Kim DS, Leppig KA, Li R, Lin S, Manzi S, Mejia AR, Pacheco JA, Pan V, Pathak J, Perry CL, Peterson JF, Prows CA, Ralston J, Rasmussen LV, Ritchie MD, Sadhasivam S, Scott SA, Smith M, Vega A, Vinks AA, Volpi S, Wolf WA, Bottinger E, Chisholm RL, Chute CG, Haines JL, Harley JB, Keating B, Holm IA, Kullo IJ, Jarvik GP, Larson EB, Manolio T, McCarty CA, Nickerson DA, Scherer SE, Williams MS, Roden DM, Denny JC.

Clin Pharmacol Ther. 2014 Oct;96(4):482-9. doi: 10.1038/clpt.2014.137. Epub 2014 Jun 24.

30.

Return of genomic results to research participants: the floor, the ceiling, and the choices in between.

Jarvik GP, Amendola LM, Berg JS, Brothers K, Clayton EW, Chung W, Evans BJ, Evans JP, Fullerton SM, Gallego CJ, Garrison NA, Gray SW, Holm IA, Kullo IJ, Lehmann LS, McCarty C, Prows CA, Rehm HL, Sharp RR, Salama J, Sanderson S, Van Driest SL, Williams MS, Wolf SM, Wolf WA; eMERGE Act-ROR Committee and CERC Committee; CSER Act-ROR Working Group, Burke W.

Am J Hum Genet. 2014 Jun 5;94(6):818-26. doi: 10.1016/j.ajhg.2014.04.009. Epub 2014 May 8.

31.

Admixture mapping and subsequent fine-mapping suggests a biologically relevant and novel association on chromosome 11 for type 2 diabetes in African Americans.

Jeff JM, Armstrong LL, Ritchie MD, Denny JC, Kho AN, Basford MA, Wolf WA, Pacheco JA, Li R, Chisholm RL, Roden DM, Hayes MG, Crawford DC.

PLoS One. 2014 Mar 3;9(3):e86931. doi: 10.1371/journal.pone.0086931. eCollection 2014.

32.

Dietary elimination therapy is an effective option for adults with eosinophilic esophagitis.

Wolf WA, Jerath MR, Sperry SL, Shaheen NJ, Dellon ES.

Clin Gastroenterol Hepatol. 2014 Aug;12(8):1272-9. doi: 10.1016/j.cgh.2013.12.034. Epub 2014 Jan 17.

33.

De-novo onset of eosinophilic esophagitis after large volume allergen exposures.

Wolf WA, Jerath MR, Dellon ES.

J Gastrointestin Liver Dis. 2013 Jun;22(2):205-8.

34.

Generalization of variants identified by genome-wide association studies for electrocardiographic traits in African Americans.

Jeff JM, Ritchie MD, Denny JC, Kho AN, Ramirez AH, Crosslin D, Armstrong L, Basford MA, Wolf WA, Pacheco JA, Chisholm RL, Roden DM, Hayes MG, Crawford DC.

Ann Hum Genet. 2013 Jul;77(4):321-32. doi: 10.1111/ahg.12023. Epub 2013 Mar 28.

35.

Managing incidental findings and research results in genomic research involving biobanks and archived data sets.

Wolf SM, Crock BN, Van Ness B, Lawrenz F, Kahn JP, Beskow LM, Cho MK, Christman MF, Green RC, Hall R, Illes J, Keane M, Knoppers BM, Koenig BA, Kohane IS, Leroy B, Maschke KJ, McGeveran W, Ossorio P, Parker LS, Petersen GM, Richardson HS, Scott JA, Terry SF, Wilfond BS, Wolf WA.

Genet Med. 2012 Apr;14(4):361-84. doi: 10.1038/gim.2012.23.

36.

Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network.

Fullerton SM, Wolf WA, Brothers KB, Clayton EW, Crawford DC, Denny JC, Greenland P, Koenig BA, Leppig KA, Lindor NM, McCarty CA, McGuire AL, McPeek Hinz ER, Mirel DB, Ramos EM, Ritchie MD, Smith ME, Waudby CJ, Burke W, Jarvik GP.

Genet Med. 2012 Apr;14(4):424-31. doi: 10.1038/gim.2012.15. Epub 2012 Feb 23.

37.

Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study.

Kho AN, Hayes MG, Rasmussen-Torvik L, Pacheco JA, Thompson WK, Armstrong LL, Denny JC, Peissig PL, Miller AW, Wei WQ, Bielinski SJ, Chute CG, Leibson CL, Jarvik GP, Crosslin DR, Carlson CS, Newton KM, Wolf WA, Chisholm RL, Lowe WL.

J Am Med Inform Assoc. 2012 Mar-Apr;19(2):212-8. doi: 10.1136/amiajnl-2011-000439. Epub 2011 Nov 19.

38.

Broad data sharing in genetic research: views of institutional review board professionals.

Lemke AA, Smith ME, Wolf WA, Trinidad SB; GRRIP Consortium.

IRB. 2011 May-Jun;33(3):1-5. No abstract available.

39.

Ethical and practical challenges of sharing data from genome-wide association studies: the eMERGE Consortium experience.

McGuire AL, Basford M, Dressler LG, Fullerton SM, Koenig BA, Li R, McCarty CA, Ramos E, Smith ME, Somkin CP, Waudby C, Wolf WA, Clayton EW.

Genome Res. 2011 Jul;21(7):1001-7. doi: 10.1101/gr.120329.111. Epub 2011 Jun 1.

40.

The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies.

McCarty CA, Chisholm RL, Chute CG, Kullo IJ, Jarvik GP, Larson EB, Li R, Masys DR, Ritchie MD, Roden DM, Struewing JP, Wolf WA; eMERGE Team.

BMC Med Genomics. 2011 Jan 26;4:13. doi: 10.1186/1755-8794-4-13.

41.

Public and biobank participant attitudes toward genetic research participation and data sharing.

Lemke AA, Wolf WA, Hebert-Beirne J, Smith ME.

Public Health Genomics. 2010;13(6):368-77. doi: 10.1159/000276767. Epub 2010 Jan 15.

42.

Nonmuscle myosin IIA with a GFP fused to the N-terminus of the regulatory light chain is regulated normally.

Kengyel A, Wolf WA, Chisholm RL, Sellers JR.

J Muscle Res Cell Motil. 2010 Sep;31(3):163-70. doi: 10.1007/s10974-010-9220-y. Epub 2010 Aug 14.

43.

Long-term motor improvement after stroke is enhanced by short-term treatment with the alpha-2 antagonist, atipamezole.

Beltran EJ, Papadopoulos CM, Tsai SY, Kartje GL, Wolf WA.

Brain Res. 2010 Jul 30;1346:174-82. doi: 10.1016/j.brainres.2010.05.063. Epub 2010 May 27.

44.

Assessing the understanding of biobank participants.

Ormond KE, Cirino AL, Helenowski IB, Chisholm RL, Wolf WA.

Am J Med Genet A. 2009 Feb;149A(2):188-98. doi: 10.1002/ajmg.a.32635.

PMID:
19161150
45.

Motor recovery and axonal plasticity with short-term amphetamine after stroke.

Papadopoulos CM, Tsai SY, Guillen V, Ortega J, Kartje GL, Wolf WA.

Stroke. 2009 Jan;40(1):294-302. doi: 10.1161/STROKEAHA.108.519769. Epub 2008 Nov 26.

46.
47.

Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy.

Wolf WA, Bieganski GJ, Guillen V, Mignon L.

Psychopharmacology (Berl). 2005 Oct;182(1):84-94. Epub 2005 Sep 29.

PMID:
15986194
48.
49.

Agonist-induced serotonin 2A receptor desensitization in the rat frontal cortex and hypothalamus.

Damjanoska KJ, Heidenreich BA, Kindel GH, D'Souza DN, Zhang Y, Garcia F, Battaglia G, Wolf WA, Van de Kar LD, Muma NA.

J Pharmacol Exp Ther. 2004 Jun;309(3):1043-50. Epub 2004 Feb 19.

PMID:
14976228
50.

SLV-308. Solvay.

Wolf WA.

Curr Opin Investig Drugs. 2003 Jul;4(7):878-82. Review.

PMID:
14619412

Supplemental Content

Support Center